阳光诺和：子公司BTP4507临床试验获批

Core Viewpoint - The company announced that its subsidiary, Jiangsu Novo Nordisk Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial application of BTP4507, which is intended for the treatment of primary hypertension patients with poor response to monotherapy [1] Group 1 - The clinical trial approval for BTP4507 marks a significant milestone in the company's drug development pipeline [1] - BTP4507 targets a specific patient population, indicating a focused approach in addressing unmet medical needs in hypertension treatment [1]